AML/MDS 细胞治疗的最新进展

Recent advances in cell therapy for AML/MDS.

CD19/BCMA 靶向 CAR-T 细胞治疗急性白血病患者抗 HLA 抗体致敏：一项初步临床研究

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Stu

B 细胞成熟抗原在急性髓系白血病中的有限表达

Limited expression of B-cell maturation antigen in acute myeloid leukemia.

早期鞘内注射地塞米松和甲氨蝶呤作为 CAR-T 细胞治疗后免疫效应细胞相关神经毒性综合征的有效方法

Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell

我们的数据提示，早期给予 IDM 可能有助于快速缓解 CAR-T 细胞治疗后的重度或类固醇难治性 ICANS，这可能为这些患者的后续治疗创造机会。

B 细胞成熟抗原是急性髓系白血病免疫治疗的新靶点

B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia.

多发性骨髓瘤的序贯靶向治疗：GPRC5D 双特异性抗体 talquetamab 作为 BCMA CAR-T 治疗的桥接

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy.

肿瘤预激 CD8⁺ 自然杀伤 T 样细胞作为复发/难治性多发性骨髓瘤的高效新型细胞疗法

Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.

TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。

CRISPR/Cas9 TCR 编辑的 NKp30 CAR-T 细胞对表达 B7H6 的白血病与黑色素瘤表现出更强的抗肿瘤免疫

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

肿瘤 CAR-T 细胞治疗：当前挑战与未来方向

CAR-T cell therapy for cancer: current challenges and future directions.

复发/难治性多发性骨髓瘤患者 CAR-T 治疗后继发治疗相关急性髓系白血病且预后不良

Therapy related acute myeloid leukemia secondary to CAR-T therapy in refractory/relapsed multiple myeloma patient showing poor prognosis.